Icron Strengthens USB Extension Patent Portfolio: related news

Newly Acquired Patent Increases Icron's USB Patent Portfolio to 19

Vancouver, BC, October 20, 2008--(T-Net)--Icron Technologies Corporation (TSX Venture: IT), the developers of ExtremeUSB®, today announced that it has acquired, from the original third party inventor, an early unassigned USB extension patent that further strengthens its existing patent portfolio on USB extension solutions. Icron's USB patent portfolio now numbers 19 issued or pending patents.

Newly Acquired Patent Increases Icron's USB Patent Portfolio to 19

Vancouver, BC, October 20, 2008--(T-Net)--Icron Technologies Corporation (TSX Venture: IT), the developers of ExtremeUSB®, today announced that it has acquired, from the original third party inventor, an early unassigned USB extension patent that further strengthens its existing patent portfolio on USB extension solutions. Icron's USB patent portfolio now numbers 19 issued or pending patents.

Icron Acquires USB Extension Patent

Vancouver, BC, October 1, 2008--(T-Net)--Icron Technologies (TSX Venture: IT), the developers of ExtremeUSB(R), today announced that it has acquired, from the original third party inventor, an early unassigned USB extension patent that further strengthens its existing patent portfolio on USB extension solutions. Icron's USB patent portfolio now numbers 19 issued or pending patents.

Halliburton Tries To Patent Form Of Patent Trolling

We see all sorts of ridiculous patent applications and patents, but my favorites tend to be the patents that have to do with patents themselves (such as the patent app on a method for filing a patent). However, the folks over at Patently-O have highlighted a fascinating patent application from an attorney at Halliburton, which appears to be an attempt to patent the process of patent trolling. The application covers, quite explicitly, having a company (we'll say Company A) that does not invent something, find a company (Company B) that did invent something, but chose to use trade secret protection, rather than patents. Then, the Company A files a patent covering Company B's technology, and then use the issued patent to get money out of Company B.

Halliburton Applies For Patent-Trolling Patent

An anonymous reader writes "Halliburton, the company many folks know as Dick Cheney's previous employer, has apparently taken an interest in methods of patent trolling. In fact, according to Techdirt, the company has applied for a patent on patent trolling. Specifically, it's applied for a patent on the process of finding a company that protected an invention via trade secret, figuring out what that secret is, patenting it ... and then suing the original company. Hopefully, the patent office rejects this patent, because I somehow doubt that Halliburton is trying to get the patent as a way to block others from patent trolling."

Patent Lawsuit Silly Season: TechCrunch Sued For Patent Infringement After Critical Blog Post

There are different levels of ridiculousness when it comes to patent lawsuits, with the lowest of the low being patent lawsuits based more on spite than on any legitimate claim. For a while, it seemed like Ray Niro's use of the infamous JPG patent, to sue a bunch companies he just didn't like, was perhaps alone in that category. But, it appears that we now have a new entrant. Apparently, some company (who we won't even name, since there's a good chance it's doing this just to get press attention) sued a more well-known competitor for patent infringement, over a location-based services patent. Looking over the patent itself it's difficult to see how it was approved. People were talking about location-based profile matching a decade ago, let alone five years ago when this patent was filed.

Icron Strengthens USB Extension Patent Portfolio

Broadband Service Provider Trident SR Sdn. Bhd.

Microsoft Employee Admits That Patent Disclosure Is A Myth

Defenders of the patent system quite frequently point out that one of the main benefits (some claim the only benefit) of the patent system is "disclosure." That is, because the patent system requires you to disclose your patent, the patent system is quite helpful in spreading ideas. This is a myth that's easily debunked on a few points. First, it only really makes sense to get patent protection if you know the idea will get disclosed or figured out anyway. In those cases, the disclosure via the patent system is meaningless, since the info would have gotten out anyway. Second, these days, thanks to "willful infringement" tripling the damages you pay, many corporations tell employees not to look at relevant patents, as it only opens up more liability.

Ameranth Receives Major Patent for Its 'Casino Poker and Dealer Management System'

SAN DIEGO, Oct. 15 /PRNewswire/ -- Ameranth, Inc. announced today that it has received an official patent grant (#7,431,650) from the United States Patent and Trademark Office for a major patent, which will have a term extending to December 2025, on its revolutionary, automated poker and dealer system invention. The patent is the result of work dating from 2001. The award of this key strategic patent confirms Ameranth's leading and pioneering role in automating the modern poker room and clearly establishes Ameranth as a technology leader in virtually all automated aspects of poker rooms as part of Ameranth's overall 21st Century Casino(TM) vision. This new patent, combined with Ameranth's portfolio of wireless/web data synchronization patents (applicable to wireless gaming and many other casino applications) and Ameranth's recent and plan

USB Implementers Forum Announces First SuperSpeed USB Developers Conference

WHAT: The SuperSpeed USB Developers Conference will provide attendees with the first opportunity to hear directly from the creators of the USB 3.0 specification, which is the technical map for device manufacturers to bring SuperSpeed USB technology to the market. Keynote speakers will address exciting advancements offered by the new technology, and attendees will obtain important information on best practices for incorporating SuperSpeed USB into their product roadmaps. In addition to technical sessions, an exhibit area will showcase the latest developments and early designs featuring SuperSpeed USB technology. WHEN: November 17-18, 2008 Members of the media and analyst communities are welcome to attend the 8:45 a.m. keynote, followed by a Q&A session and luncheon on November 17.

Novo Nordisk Assigns Inhaled Insulin Patent Portfolio to Aradigm

transferred to Aradigm, at no charge, a portfolio of inhaled insulin related patents pursuant to a license agreement between Aradigm and Novo that was terminated in May 2008. Novo purchased a significant portion of the portfolio from Aradigm in July 2006 and supplemented the portfolio with certain of its own related patents. The portfolio includes both U.S. and foreign patents. Aradigm assumes responsibility for the maintenance of this portfolio.

Novo Nordisk Assigns Inhaled Insulin Patent Portfolio to Aradigm

Aradigm Corporation (OTCBB:ARDM) ("Aradigm" or "Company"), a specialty pharmaceutical company, today announced that Novo Nordisk ("Novo") transferred to Aradigm, at no charge, a portfolio of inhaled insulin related patents pursuant to a license agreement between Aradigm and Novo that was terminated in May 2008. Novo purchased a significant portion of the portfolio from Aradigm in July 2006 and supplemented the portfolio with certain of its own related patents. The portfolio includes both U.S. and foreign patents. Aradigm assumes responsibility for the maintenance of this portfolio.

Novo Nordisk Assigns Inhaled Insulin Patent Portfolio to Aradigm

HAYWARD, Calif.--(BUSINESS WIRE)--Oct 8, 2008 - Aradigm Corporation (OTCBB:ARDM) ("Aradigm" or "Company"), a specialty pharmaceutical company, today announced that Novo Nordisk ("Novo") transferred to Aradigm, at no charge, a portfolio of inhaled insulin related patents pursuant to a license agreement between Aradigm and Novo that was terminated in May 2008. Novo purchased a significant portion of the portfolio from Aradigm in July 2006 and supplemented the portfolio with certain of its own related patents. The portfolio includes both U.S. and foreign patents. Aradigm assumes responsibility for the maintenance of this portfolio.

Novo Nordisk Assigns Inhaled Insulin Patent Portfolio to Aradigm

HAYWARD, Calif.--(BUSINESS WIRE)--Oct 8, 2008 - Aradigm Corporation (OTCBB:ARDM) ("Aradigm" or "Company"), a specialty pharmaceutical company, today announced that Novo Nordisk ("Novo") transferred to Aradigm, at no charge, a portfolio of inhaled insulin related patents pursuant to a license agreement between Aradigm and Novo that was terminated in May 2008. Novo purchased a significant portion of the portfolio from Aradigm in July 2006 and supplemented the portfolio with certain of its own related patents. The portfolio includes both U.S. and foreign patents. Aradigm assumes responsibility for the maintenance of this portfolio.

Patent licensing after the Quanta decision

Patent owners have turned their attention to the terms and conditions of patent licenses now that the Supreme Court has recently expanded the scope of patent exhaustion through its Quanta Computer v. LG Electronics decision. "Patent exhaustion" is a term of art that generally means a patent owner can profit from the sale of a product covered by the patent only until the first sale of the product.

Arkados Awarded Patent on Universal Network Adapter Technology

announced today that it has been awarded a United States patent entitled "Integrated Universal Network Adapter." The U.S. Patent & Trademark Office awarded patent 7,440,443 to Arkados on August 2, 2008. The patent describes the concept of making physical network connections transparent to the user, by incorporating MAC/PHY technology that can adapt to different physical media into a single chip. In turn, this chip can be used to create products that can bridge between different physical media connections. The patent also describes a technique to dynamically choose the best medium to use based on data about the medium and the QoS requirements. The patent describes a common Medium Access Controller (MAC) and Physical Layer (PHY) communications interface that has an adapter allowing simultaneous communication over multiple media, such as pow

Benitec gets 'Control of Gene Expression' patent in New Zealand

Benitec Limited announced that a key patent 'Control of Gene Expression' part of the Graham patent family of RNA interference (RNAi) patents was granted in New Zealand. The "Control of Gene Expression patent" is a patent in the foundational Graham RNAi patent family and is related to the '099 patent currently under re-examination at the USPTO.

Court Stays Patent Infringement Suit Brought against Candela byPalomar

Candela Corporation (NASDAQ: CLZR) announced today that the United States District Court for the District of Massachusetts agreed to stay the patent litigation that Palomar Medical Technologies, Inc. (�Palomar�) brought against the Company in August 2006. In that suit, Palomar asserts that the Company infringed upon U.S. Patent No. 5,735,844 (the ‘ “844 Patent�) and U.S. Patent No. 5,595,568, which is related to the ‘844 Patent (the ‘ “568 Patent�).

Court Stays Patent Infringement Suit Brought against Candela by Palomar

Candela Corporation (NASDAQ: CLZR) announced today that the United States District Court for the District of Massachusetts agreed to stay the patent litigation that Palomar Medical Technologies, Inc. (�Palomar�) brought against the Company in August 2006. In that suit, Palomar asserts that the Company infringed upon U.S. Patent No. 5,735,844 (the ‘ “844 Patent�) and U.S. Patent No. 5,595,568, which is related to the ‘844 Patent (the ‘ “568 Patent�).

Benitec Limited (ASX:BLT) Graham Gene Silencing Patent Granted in New Zealand

MELBOURNE, Australia, Oct 17, 2008 - Benitec Limited (ASX:BLT)(PINK:BNIKF) today announced that a key patent "Control of Gene Expression" part of the Graham patent family of RNA interference (RNAi) patents was granted in New Zealand. The "Control of Gene Expression patent" is a patent in the foundational Graham RNAi patent family and is related to the '099 patent currently under reexamination at the USPTO.

::: Axis-Shield Afinion HbA1c patent granted in Japan

Dundee, Scotland, 15 October, 2008: Axis-Shield (LSE:ASD, OSE:ASD), the international in-vitro diagnostics company, today announces that it has received notice of approval for its Japanese patent application governing the measuring methodology for HbA1c within the Afinion™ cassette for detection of this important marker of diabetic patient compliance. The patent protects technology which improves HbA1c stability, precision and accuracy and has resulted in a longer product shelf-life with improved performance. We continue to strengthen our Afinion™ -related patent protection and this latest addition to our IP portfolio for Afinion™ complements US patent approval for design of the Afinion HbA1c cassette and notices of patent approval already received in Europe, China and Japan for applications covering the core technology.

CSMG Technologies Announces Key Fifth U.S. Tissue Bonding/Welding Patent Approved

a technology management company, announced the company has received approval of its fifth U.S. patent. The approval is on a key divisional application for "Bonding of Soft Biological Tissues by Passing High Frequency Electric Current Therethrough" for CSMG Technologies subsidiary Live Tissue Connects ("LTC") platform tissue bonding/welding technology. The patent approval follows the issuance of four other U.S. patents, a European Union patent, in eight European countries, Ukraine, Canada and Australia with 14 U.S. and international patents pending. Donald S. Robbins, President and CEO of CSMG Technologies, said, "This key U.S. patent approval re-enforces our patent portfolio and expands LTC's commercial possibilities while increasing our shareholder value.

Search took 0.26 seconds.